The esketamine nasal spray – sold as Spravato by Johnson & Johnson – is the first new class of depression drug subsidised by the Pharmaceutical Benefits Scheme in more than 30 years.

The first quarter of 2025 saw mixed results, with revenue dipping by 2% year over year to $11.1 billion. Net income, however, ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.

Johnson & Johnson (NYSE ... Analysts expect Spravato, a nasal spray for adults with treatment-resistant depression, to garner $2.1 billion to $2.3 billion of sales, but internal company estimates ...

The drug - which comes in the form of a nasal spray - is a chemical cousin ... the quality of life for thousands of Australians. Johnson & Johnson Innovative Medicine ANZ managing director Joana ...

The federal government in March canceled a $385,000 grant it awarded to a University of Montana vaccine epidemiologist and ...

Demand for psychedelics-assisted psychotherapy is increasing in Switzerland, but patients still have to wait up to a year.